- Home
- CDIO vs KALA Comparison
CDIO vs KALA Comparison
Compare CDIO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- KALA
- Stock Information
- Founded
- CDIO 2017
- KALA 2009
- Country
- CDIO United States
- KALA United States
- Employees
- CDIO N/A
- KALA N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- KALA Health Care
- Exchange
- CDIO Nasdaq
- KALA Nasdaq
- Market Cap
- CDIO 6.8M
- KALA 5.5M
- IPO Year
- CDIO N/A
- KALA 2017
- Fundamental
- Price
- CDIO $3.71
- KALA $0.73
- Analyst Decision
- CDIO
- KALA Buy
- Analyst Count
- CDIO 0
- KALA 3
- Target Price
- CDIO N/A
- KALA $31.50
- AVG Volume (30 Days)
- CDIO 35.2K
- KALA 544.6K
- Earning Date
- CDIO 11-14-2025
- KALA 11-07-2025
- Dividend Yield
- CDIO N/A
- KALA N/A
- EPS Growth
- CDIO N/A
- KALA N/A
- EPS
- CDIO N/A
- KALA N/A
- Revenue
- CDIO $19,507.00
- KALA N/A
- Revenue This Year
- CDIO $1,434.82
- KALA N/A
- Revenue Next Year
- CDIO $4,661.91
- KALA N/A
- P/E Ratio
- CDIO N/A
- KALA N/A
- Revenue Growth
- CDIO N/A
- KALA N/A
- 52 Week Low
- CDIO $3.22
- KALA $0.70
- 52 Week High
- CDIO $53.10
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- CDIO 44.85
- KALA 26.91
- Support Level
- CDIO $3.58
- KALA $0.70
- Resistance Level
- CDIO $3.99
- KALA $0.79
- Average True Range (ATR)
- CDIO 0.30
- KALA 0.06
- MACD
- CDIO -0.04
- KALA 0.39
- Stochastic Oscillator
- CDIO 24.48
- KALA 23.63
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.